EG24409A - N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases - Google Patents

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Info

Publication number
EG24409A
EG24409A EG20010550A EG20010550A EG24409A EG 24409 A EG24409 A EG 24409A EG 20010550 A EG20010550 A EG 20010550A EG 20010550 A EG20010550 A EG 20010550A EG 24409 A EG24409 A EG 24409A
Authority
EG
Egypt
Prior art keywords
oxazolyl
thiazolyl
thio
alkyl
methyl
Prior art date
Application number
EG20010550A
Inventor
Raj N Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24409A publication Critical patent/EG24409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20010550A 2000-07-26 2001-05-23 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases EG24409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles

Publications (1)

Publication Number Publication Date
EG24409A true EG24409A (en) 2009-05-20

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010550A EG24409A (en) 2000-07-26 2001-05-23 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Country Status (26)

Country Link
EP (1) EP1303513A1 (en)
JP (1) JP2004509857A (en)
KR (1) KR20030016429A (en)
CN (1) CN100457753C (en)
AR (1) AR030563A1 (en)
AU (1) AU2001259704A1 (en)
BG (1) BG65132B1 (en)
BR (1) BR0112674A (en)
CA (1) CA2417254A1 (en)
CZ (1) CZ2003237A3 (en)
EE (1) EE200300041A (en)
EG (1) EG24409A (en)
GE (1) GEP20043367B (en)
HR (1) HRP20030116A2 (en)
HU (1) HUP0303698A2 (en)
IL (2) IL153591A0 (en)
LV (1) LV13037B (en)
MX (1) MXPA03000774A (en)
MY (1) MY129635A (en)
NO (1) NO20030394L (en)
PL (1) PL365170A1 (en)
SI (1) SI21099A (en)
SK (1) SK18392002A3 (en)
TW (1) TWI302533B (en)
WO (1) WO2002010162A1 (en)
YU (1) YU4903A (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
ES2346204T3 (en) 2002-09-04 2010-10-13 Schering Corporation SUITABLE PYRAZOLOPIRIMIDINS FOR THE TREATMENT OF CANCER DISEASES.
AU2003265901B2 (en) 2002-09-04 2006-09-14 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003275031B2 (en) 2002-09-23 2006-08-17 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
MXPA05003120A (en) 2002-09-23 2005-06-22 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors.
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (en) * 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
CA2619790A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
WO2007032936A2 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
RU2008117298A (en) 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Pyrazolopyrimidines as Protein Kinase Inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2007146039A2 (en) * 2006-06-06 2007-12-21 Bristol-Myers Squibb Company Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
JP5063700B2 (en) 2006-10-31 2012-10-31 シェーリング コーポレイション Anilinopiperazine derivatives and methods using anilinopiperazine derivatives
WO2008054749A1 (en) 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CN101678002A (en) 2007-05-08 2010-03-24 先灵公司 Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
EP2831282B1 (en) 2012-03-30 2018-07-04 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
US9944670B2 (en) * 2013-12-04 2018-04-17 Hangzhou Yuanchang Medical Sci-Tech Co., Ltd Gemcitabine derivatives, compositions comprising same and pharmaceutical applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ES2237919T4 (en) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company AMINOTIAZOL INHIBITORS REPLACED WITH CARBON OF CYCLINE DEPENDENT KINASES.
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
KR20030016429A (en) 2003-02-26
IL153591A0 (en) 2003-07-06
BR0112674A (en) 2003-12-30
CN100457753C (en) 2009-02-04
MXPA03000774A (en) 2003-09-10
BG65132B1 (en) 2007-03-30
SK18392002A3 (en) 2003-09-11
JP2004509857A (en) 2004-04-02
CA2417254A1 (en) 2002-02-07
WO2002010162A1 (en) 2002-02-07
LV13037B (en) 2003-11-20
CN1444584A (en) 2003-09-24
HRP20030116A2 (en) 2005-02-28
AR030563A1 (en) 2003-08-27
TWI302533B (en) 2008-11-01
GEP20043367B (en) 2004-06-10
HUP0303698A2 (en) 2004-04-28
IL153591A (en) 2009-07-20
BG107468A (en) 2004-01-30
CZ2003237A3 (en) 2003-06-18
SI21099A (en) 2003-06-30
EE200300041A (en) 2005-04-15
NO20030394L (en) 2003-03-03
MY129635A (en) 2007-04-30
YU4903A (en) 2006-03-03
EP1303513A1 (en) 2003-04-23
NO20030394D0 (en) 2003-01-24
PL365170A1 (en) 2004-12-27
AU2001259704A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
EG24409A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
HK1049661B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases
HK1049662A1 (en) Aminothiazole inhibitors of cyclin dependent kinases
HUP0300974A3 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use
EG24028A (en) Aminothiazole inhibitors of cyclin dependent kinases
AU2002213485A1 (en) Inhibitors of protein kinases
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
HU0304052D0 (en) Heterocyclic inhibitors of erk2 and uses thereof
AU5553801A (en) Heterocycles that are inhibitors of impdh enzyme
AU8969601A (en) New use of lipase inhibitors
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2001216218A1 (en) Heterocyclic analgesic compounds and method of use thereof
GB0015904D0 (en) Inhibitors of HPV E1 helicase enzyme
IL137929A0 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU2001229727A1 (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
AU2001259990A1 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU2002358874A1 (en) 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
AU2001245741A1 (en) Antisense inhibition of adam10 expression
IL152792A0 (en) Heterocycle derivatives and methods of use
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2002212162A1 (en) Incompetitive inhibitors of helicase primase
IS6696A (en) N- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibits cyclin-dependent kinases
AU1212002A (en) Use of lipase inhibitors
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors